AzTrials
AzTrials

Breast CancerALDRAMNCT05796219

Automated Low Dose Risk Assessment Mammography (ALDRAM)

A study testing Low dose mammogram in people with Breast Cancer, run by Manchester University NHS Foundation Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Breast cancer (BC) is the commonest cause of death in young women. Breast screening in women aged 35-45, at increased risk due to their family history, has been shown to improve survival. However, 80% of women who develop BC do not have a family history. Read more about this study

Who is it for?
Ages 30 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Breast Cancer
What is being tested?
Low dose mammogram
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
154 participants
Where
1 siteUnited Kingdom
Study dates
22 Feb 2019to 16 Feb 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Females with moderate to high risk of breast cancer, identified through and attending for annual review and mammography at the family history clinic, Nightingale Centre, Manchester
  • Current age 30-45 years
  • Capable of providing informed consent to a patient information sheet written in English

Who cannot join

  • Prior breast cancer
  • Prior breast augmentation or reduction
  • Participation in the TARA-Prev study which included an additional mammogram and thus radiation dose

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • The Nightingale Centre

    Manchester, M23 9LT

Other trials in United Kingdom

About this study

Official title: Technical Development of Automated Low Dose Risk Assessment Mammography (ALDRAM) in Women Attending for Annual Mammography Through a Family History Clinic

Breast cancer (BC) is the commonest cause of death in young women. Breast screening in women aged 35-45, at increased risk due to their family history, has been shown to improve survival. However, 80% of women who develop BC do not have a family history. Numerous studies have shown that high mammographic density (MD) is one of the strongest risk factors for BC development. Full field digital mammography (FFDM) can be used to assess MD, however it is not recommended for population BC screening in those <40 years of age due to the concerns about the use of ionising radiation. Safe and accurate high throughput methods to quantify MD in young women are thus required to improve risk prediction and reduce BC mortality. This study aims to develop a low dose mammogram, with quantification of density using artificial intelligence, to facilitate high throughput risk assessment in young women. 600 women aged 30-45, previously identified as being at increased risk of BC and attending for annual mammography at The Nightingale Centre will be recruited. Participants will undergo FFDM of the right breast as usual, however, following acquisition of the craniocaudal (CC) view, the breast will remain compressed and the mammogram dose reduced by 90% to deliver a LD mammogram. This process will be repeated for the right medio-lateral oblique (MLO) view. The left breast FFDM will proceed as normal. It is estimated that each extra exposure will take 1-2 minutes only. Deep machine learning methods will be used to define the relationship between standard FFDM views and their low dose counterparts and determine which view (CC vs MLO) provides the best correlation to be taken forward to the next stage of the research.

Read the detailed description

The more prolonged compression of the breast required to acquire the LD images may cause some additional breast discomfort. However, in a similar study in The Netherlands only 1% of women could not tolerate the procedure.

Participants will receive an extra dose of ionising radiation amounting to 20% of the radiation dose of a single FFDM view (of which 4 are usually taken, 2 on each breast). The risks associated with this are described in section B and entered into the PIS.

The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.

The two key objectives are:

  1. To develop machine learning methods for automated quantification of mammographic density using low dose mammograms in a study of 600 women attending for annual Full Field Digital Mammography (FFDM).
  2. To validate Automated Low Dose Risk Assessment Mammography (ALDRAM) against automated FFDM assessment that has been shown to predict BC risk.

Breast cancer is the commonest of all causes of death in young women. Currently the only factor triggering referral to risk assessment clinics is the presence of a family history. Although this is known to confer increased risk, only 20% of young women who develop BC actually have such a family history of the disease. Thus 80% of cases come 'out of the blue' and methods to assess risk in the general population are required if we are to improve survival (screening in those at increased risk aged 35-45 has been shown to reduce mortality). High mammographic density has been shown in multiple studies to confer significantly increased risk of BC, however population screening with full field digital mammograms is not recommended in those <40 primarily due to the reduced sensitivity and use of a moderate doses of ionising radiation. There is thus an urgent need for safe, high throughput, techniques to accurately define mammographic density in young women - the purpose of this study. Following consent and initial Case Report Form (CRF) completion, mammography will commence as standard. The right breast craniocaudal (CC) view will be performed first and the steps below followed:

  1. The breast will be positioned as standard for the CC view.
  2. The Automatic Optimisation of Parameters (AOP; also known as Automatic Exposure Control (AEC)) will be performed for target, filter, Peak KiloVoltage (kVp) and MilliAmpere second (mAs) selection for Full Field Digital Mammography (FFDM).
  3. The full field CC view will be performed as standard.
  4. The breast will remain compressed whilst the radiographer manually reduces the mAs by 90% or to the minimum value of 4 mAs (the machine does not deliver less than 4 mAs). No other parameters will be changed. A repeat CC exposure at this reduced dose will be performed.
  5. The machine will be reset to automatic and the subsequent mediolateral oblique (MLO) view will be obtained and the low dose view performed again as above.
  6. The left breast CC and MLO views will then be obtained as standard.
  7. This concludes the woman's participation in the study. The images from the low dose and FFDMs will then be processed to determine whether mammographic density from low dose mammograms correlates with that from FFDM and what modifications are required to automated algorithms for future studies.
Conditions
Breast Cancer
Being tested
Low dose mammogram
Keywords
Low dose mammogram
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low dose mammogramRadiation

    Low dose mammogram

Study groups in NCT05796219
Study groupRoleWhat they receive
Low dose mammogramOtherLow dose mammo to compare with standard mammo
Receives: Radiation: Low dose mammogram

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between full dose and low dose percent mammographic density estimates

    Full dose and Low dose mammograms will be analysed using an established AI technique, the predicted Visual Analogue Score (pVAS), to determine the percent mammographic density (%MD). Correlation between the full and low dose image derived %MD across the whole study population will be assessed using Pearson correlation coefficient.

    Measured: The low dose mammogram will be taken immediately after the full dose exposure, under the same breast compression.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Apr 2023
  2. Study start22 Feb 2019
  3. Primary completion5 May 2020
  4. Study completion16 Feb 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Model description
The research question for this study is whether an automated, low dose mammogram can be developed to provide an accurate assessment of mammographic density, and thus breast cancer risk, in women aged 30-45.
Masking
None (open label)
Enrolment
154 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05796219
Sponsor's protocol ID
B00394
Acronym
ALDRAM
Status last verified
Mar 2023
First submitted
22 Mar 2022
Last updated
3 Apr 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Share Protocol

Questions about this trial

What is this clinical trial studying?

A study testing Low dose mammogram in people with Breast Cancer, run by Manchester University NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between full dose and low dose percent mammographic density estimates (time frame: The low dose mammogram will be taken immediately after the full dose exposure, under the same breast compression.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in